Hematologic Oncology

Acalabrutinib yielded durable organ-specific responses and a manageable safety profile in patients with steroid-refractory chronic graft-vs-host disease.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

Tagraxofusp was well tolerated and yielded modest efficacy signals as monotherapy in myelofibrosis.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

The FDA has approved a 375-mg vial of nelarabine for intravenous administration in both T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Sofi-cel has received FDA breakthrough therapy designation for heavily pretreated patients with relapsed/refractory T-ALL and T-LBL.

The FDA has granted fast track designation to gamgertamig for autoimmune hemolytic anemia and immune thrombocytopenia.

Epcoritamab displayed a significant PFS benefit vs chemotherapy in relapsed/refractory DLBCL.

The FDA issued a CRL for tabelecleucel in EBV+ PTLD, a BLA was submitted for an ivonescimab regimen in EGFR-mutated NSCLC, and more.

ICT01 has received FDA breakthrough therapy designation as frontline therapy for patients with AML who are unfit for induction chemotherapy.

A target action date of August 30, 2026, has been set for the FDA's decision regarding the sBLA seeking the approval of ropeginterferon alfa-2b for ET.

FDA announces new CRL for tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease.

A rusfertide NDA for polycythemia vera has been submitted to the FDA, a tafasitamab combination boosts PFS over R-CHOP in DLBCL, and more.

Tsewang Tashi, MD, expands on long-term bone health data with avapritinib in patients with indolent systemic mastocytosis from the PIONEER trial.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.

Obe-cel produced responses and low rates of high-grade CRS and ICANS in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Tafasitamab/lenalidomide added to first-line R-CHOP improved PFS vs R-CHOP alone with no new safety signals in patients with DLBCL.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

The FDA has received a new drug application seeking the approval of bezuclastinib for the treatment of patients with non-advanced systemic mastocytosis.

Lodovico Balducci, MD, built a new discipline from the ground up, which kick-started pivotal research in geriatric oncology.

NXC-201 demonstrated organ responses in 70% of evaluable patients with relapsed/refractory light chain amyloidosis.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.